Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Multiple Myeloma Advanced 2026

Hartmut Goldschmidt

哈特穆特·戈尔德施密特

MD

🏢University Hospital Heidelberg(海德堡大学医院)🌐Germany

Professor of Internal Medicine and Hematology-Oncology; Head, Myeloma Section; Coordinator, GMMG Study Group内科与血液肿瘤科教授;骨髓瘤科主任;GMMG研究组协调员

61
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Hartmut Goldschmidt, MD is Professor of Hematology-Oncology and Head of the Myeloma Section at University Hospital Heidelberg. As founding coordinator of the German-Speaking Myeloma Multicenter Group (GMMG), he has led landmark German myeloma trials on transplant, consolidation, and lenalidomide maintenance. His GMMG-HD trials have defined treatment standards across German-speaking Europe.

Share:

🧪Research Fields 研究领域

Lenalidomide Maintenance来那度胺维持治疗
GMMG Trial NetworkGMMG试验网络
Myeloma Consolidation and Maintenance骨髓瘤巩固与维持治疗
Autologous Transplant Optimization自体移植优化
High-Risk Myeloma Cytogenetics高危骨髓瘤细胞遗传学

🎓Key Contributions 主要贡献

Lenalidomide Maintenance After ASCT

Led GMMG-MM5 and contributed to CONTINUOUS trials establishing lenalidomide maintenance as standard of care after autologous transplantation, demonstrating significant improvement in PFS and establishing duration-of-therapy guidelines.

GMMG Cooperative Group Leadership

Founded and coordinates the GMMG Study Group, which conducts large phase III myeloma trials in Germany, Austria, and Switzerland. GMMG trials have enrolled thousands of patients and produced practice-changing data on induction, transplant, and maintenance strategies.

Representative Works 代表性著作

[1]

Lenalidomide, Adriamycin, and Dexamethasone versus Bortezomib, Adriamycin, and Dexamethasone as Induction Therapy in Newly Diagnosed Multiple Myeloma (GMMG-MM5)

Journal of Clinical Oncology (2019)

Phase III GMMG-MM5 trial comparing RAD vs PAD induction plus lenalidomide maintenance, establishing lenalidomide consolidation and maintenance outcomes in German transplant-eligible NDMM.

[2]

Carfilzomib, Lenalidomide, and Dexamethasone as Induction and Maintenance Therapy with Autologous Stem Cell Transplantation (GMMG-HD6)

The Lancet Oncology (2022)

Phase III GMMG-HD6 randomized trial of KRd vs VRd induction showing KRd improved MRD negativity rates in transplant-eligible NDMM, influencing induction selection in high-risk patients.

🏆Awards & Recognition 奖项与荣誉

🏆German Cancer Society (DKG) Clinical Oncology Award
🏆German Society of Hematology and Medical Oncology (DGHO) Lifetime Achievement Award
🏆Heidelberg University Medical Faculty Research Prize
🏆GMMG Group Distinguished Service Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 哈特穆特·戈尔德施密特 的研究动态

Follow Hartmut Goldschmidt's research updates

留下邮箱,当我们发布与 Hartmut Goldschmidt(University Hospital Heidelberg)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment